122
Participants
Start Date
October 4, 2022
Primary Completion Date
November 29, 2024
Study Completion Date
November 29, 2024
GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system
Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1
Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2
Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
GSK Investigational Site, Leuven
GSK Investigational Site, Hamburg
GSK Investigational Site, Magdeburg
GSK Investigational Site, Cologne
GSK Investigational Site, Cambridge
Lead Sponsor
GlaxoSmithKline
INDUSTRY